Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuralstem Inc.

www.neuralstem.com

Latest From Chiesi Farmaceutici SPA

Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule

GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.

Drug Approval Standards Respiratory

Chiesi Wins EU Nod For COPD Triple Combo, But Partner Is Predicted For Launch

Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.

Approvals Respiratory

White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies

UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.

Commercial Business Strategies

Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • NeuralStem BioPharmaceuticals Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neuralstem Inc.
  • Senior Management
  • Richard Daly, Pres. & CEO
    Jonathan Lloyd Jones, CFO
    Karl Johe, PhD, CSO
    Thomas G Hazel, PhD, SVP, Research
  • Contact Info
  • Neuralstem Inc.
    Phone: (301) 366-4960
    20271 Goldenrod Lane
    2nd Floor
    Germantown, MD 20876
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register